An experimental study found that the accumulation of amyloid-β in mice and humans could result in sleep disorders (68), and studies also indicated that subjective indicators such as poor sleep quality were correlated with an increased cortical amyloid-β burden, and that the level of amyloid-β in the cerebrospinal fluid was correlated with the level of phosphorylated tau (69, 70). The gene discussed is MAPT; the disease is sleep disorder.